Epigenomics AG Release: Week In Review: Cathay Fortune Pays $186 Million For German Diagnostic Company

Cathay Fortune, a Shanghai PE firm, will pay $186 million to acquire Berlin's Epigenomics and its blood plasma colorectal cancer test; Singapore's Aslan Pharma will conduct a Taiwan IPO in May and begin trading in June; EpimAb of Shanghai closed a $25 million Series A round to develop bispecific antibodies; Shanghai's Zai Lab acquired China rights to a novel antibiotic for drug-resistant infections from Paratek Pharma of Boston; HitGen of Chengdu will work with San Diego's Scripps Research Institute to discover novel small molecule drug candidates, its fourth new collaboration in three months; Denovo Biopharma, a San Diego-Hangzhou company, in-licensed a CNS drug candidate from Albany Molecular Research; Digital China Holdings established the China Healthcare Big Data Development Co. with China ministries and state-owned enterprises; two China companies participated in a Series B funding for the UK's Congenica and its clinical genomics software; Bristol-Myers Squibb received CFDA approval of its direct-acting, all oral, interferon-free hepatitis C regimen; and Aslan Pharma will start a global Phase III trial of its lead drug candidate in patients with biliary tract cancer.